PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-30.95%
Both yoy net incomes decline, with AXSM at -16.07%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-12.50%
Negative yoy D&A while AXSM is 8.85%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Negative yoy SBC while AXSM is 5.90%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
710.07%
Well above AXSM's 436.14% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
478.18%
A yoy AP increase while AXSM is negative at -42.43%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
8.45%
Lower 'other working capital' growth vs. AXSM's 354.18%. David Dodd would see fewer unexpected short-term demands on cash.
-100.00%
Both negative yoy, with AXSM at -82.62%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-8.11%
Negative yoy CFO while AXSM is 43.68%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth well above AXSM's 46.94%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AXSM's 46.94%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-50.00%
Both yoy lines negative, with AXSM at -14.11%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-32.24%
Negative yoy issuance while AXSM is 610.92%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.